On November 19, 2021 Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, reported the release of 9 abstracts that will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzalez Convention Center in San Antonio, Texas, from December 7-10, 2021 (Press release, Puma Biotechnology, NOV 19, 2021, View Source [SID1234595856]). Abstracts are available to the public online on the SABCS website at www.sabcs.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation:
Abstract:
GS4-10
Title:
Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
Presenter:
Komal Jhaveri, MD, FACP
Session:
Friday, Dec. 10, 11:00-11:15 a.m. CT
Poster Presentations:
Abstract:
P2-10-08
Title:
Assessment of risk factors for HER2+ breast cancer recurrence: A literature review
Presenter:
Joyce O’Shaughnessy, M.D.
Session:
Poster Session 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
Abstract:
P2-11-02
Title:
Subsequent breast cancer among women with HER2+ disease in a large integrated healthcare system
Presenter:
Reina Haque, PhD, MPH
Session:
Poster Session 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
Abstract:
P2-11-19
Title:
Estimating the long-term risk of recurrence in patients receiving HER2-targeted agents in HER2+ early-stage breast cancer (ESBC)
Presenter:
David Leroy Veenstra, PharmD, PhD
Session:
Poster Session 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
Abstract:
P2-13-05
Title:
Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC)
Presenter:
Nancy U. Lin, MD
Session:
Poster Session 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
Abstract:
P2-13-21
Title:
Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial
Presenter:
Frankie Ann Homes, MD, FACP
Session:
Poster Session 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
Abstract:
P3-12-20
Title:
Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer
Presenter:
Joyce O’Shaughnessy, M.D.
Session:
Poster Session 3, Thursday, Dec. 9, 7:00-8:30 a.m. CT
Abstract:
P3-16-01
Title:
Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
Presenter:
David Leroy Veenstra, PharmD, PhD
Session:
Poster Session 3, Thursday, Dec. 9, 7:00-8:30 a.m. CT
Abstract:
P5-18-02
Title:
Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer
Presenter:
Arlene Chan, MBBS, FRACP, MMED
Session:
Poster Session 5, Friday, Dec. 10, 7:00-8:30 a.m. CT